At the Intersection of Science and Law

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/5e/b5/34/5eb534a8-ffe2-2455-ddff-eb0eadd77851/mza_8788355609034046974.jpg/600x600bb.jpg

DLA Piper

14 episodes

6 months ago

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

All content for At the Intersection of Science and Law is the property of DLA Piper and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Technology,

Science

Episodes (14/14)

At the Intersection of Science and Law

Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year.

4 months ago

29 minutes

At the Intersection of Science and Law

Life sciences companies and the risks posed by the mifepristone litigation

1 year ago

33 minutes

At the Intersection of Science and Law

Trade secrets protection in the life sciences sector

1 year ago

21 minutes

At the Intersection of Science and Law

Cross-border considerations for privacy in clinical trials

2 years ago

18 minutes

At the Intersection of Science and Law

Global Life Sciences Supply Chain Insights

2 years ago

27 minutes

At the Intersection of Science and Law

AI risk assessments: Future-proofing your innovation when rules can change mid-game

2 years ago

24 minutes

At the Intersection of Science and Law

The rise of global telehealth

2 years ago

25 minutes

At the Intersection of Science and Law

Advising the advisor: Tips for navigating the life sciences and regulatory environment

2 years ago

31 minutes

At the Intersection of Science and Law

The moral imperative: Balancing innovation, regulation and prescription drug availability

3 years ago

30 minutes

At the Intersection of Science and Law

Incentivizing diverse representation in clinical trials

3 years ago

22 minutes

At the Intersection of Science and Law

The crossroad of science and law

In this episode, DLA Piper’s Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters...

3 years ago

26 minutes

At the Intersection of Science and Law

Social media’s impact on the life sciences industry

In this episode, DLA Piper’s Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public's view of medicine and science and how that in turn impacts the life...

3 years ago

34 minutes

At the Intersection of Science and Law

Understanding AI and its use in drug discovery

DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.

3 years ago

31 minutes

At the Intersection of Science and Law

mRNA technology and the COVID-19 vaccine: A conversation with Pfizer’s Kathy Fernando

For decades, scientists have studied the seemingly endless possibilities of custom-made messenger RNA, or mRNA. Kathy Fernando, Head Vice President, Worldwide of Clinical Operations at Pfizer, spent her early bench science career working with mRNA...

3 years ago

26 minutes